CosmosID is a microbial genomics platform focused on rapid characterization of microorganisms, pathogens and
anti-microbial resistance for infectious disease identification, food safety inspections, pharmaceutical discovery, public health surveillance and microbiome analysis

Here's an overview!

Photo by agsandrew/iStock / Getty Images

Fast

From a post-sequencing metagenomic sample we identify bacteria, DNA viruses, fungi, parasites, antibiotic resistance and virulence genes, and more within minutes.

Photo by Martin Barraud/OJO Images / Getty Images

Accurate

With the use of our curated genome databases and both sensitivity and specificity >95% we are unmatched in our ability to detect microorganisms in metagenomic samples.

reduced Total cost Of Care

The speed and universal nature of the test, and the ability to detect both pathogens and antimicrobial resistance genes at once will improve patient outcomes, shortening the length of hospitalization and avoiding complex therapies to significantly reduce total cost of care.

      
                  “
                    "CosmosID can provide the resolution necessary for genomic sequencing of pathogens to become a reality in the shift to precision medicine."
                  ”
                
                —
                  George Watts, Co-Director of the Genomic Center at University of Arizona 
                
                  “
                    "I have explored the microbiome of everything from the NY subway to outer space and the software analysis component is critically important. CosmosID provides a robust tool for the quantification and detection of microorganisms and antimicrobial resistance markers and we are actively using it for onsite in situ diagnostics."
                  ”
                
                —
                  Chris Mason, Associate Professor in Genetics from Weil Cornell Medical School 
                
                  “
                    "The precise strain level identification that CosmosID provides could revolutionize clinical microbiology, directing physicians towards improved and more effective treatment options."
                  ”
                
                —
                 Ashok Chopra, professor of microbiology and immunology at University of Texas Medical Branch
                
                  “
                    "We first sent specimens to [CosmosID] in late October, and we are already talking to them about results, so for me that was impressive that we were able to get such fast turnaround.
I was impressed by the number of species that were identified, particularly ones in lower abundance."
                  ”
                
                —
                  Christopher Coe, professor of psychology at The University of Wisconsin-Madison